BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ando T, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Sugito N, Mori R, Ogawa R, Katada T, Fujii Y. Relationship between expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in esophageal carcinoma cell lines. Dis Esophagus. 2008;21:15-20. [PMID: 18197934 DOI: 10.1111/j.1442-2050.2007.00700.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Hahnvajanawong C, Chaiyagool J, Seubwai W, Bhudhisawasdi V, Namwat N, Khuntikeo N, Sripa B, Pugkhem A, Tassaneeyakul W. Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil. World J Gastroenterol 2012; 18(30): 3955-3961 [PMID: 22912546 DOI: 10.3748/wjg.v18.i30.3955] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 61] [Article Influence: 1.9] [Reference Citation Analysis]
2 Chen J, Lu H, Yan D, Cui F, Wang X, Yu F, Xue Y, Feng X, Wang J, Wang X, Jiang T, Zhang M, Zhao S, Yu Y, Tang H, Peng Z. PAK6 increase chemoresistance and is a prognostic marker for stage II and III colon cancer patients undergoing 5-FU based chemotherapy. Oncotarget 2015;6:355-67. [PMID: 25426562 DOI: 10.18632/oncotarget.2803] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
3 Chung T, Na J, Kim YI, Chang DY, Kim YI, Kim H, Moon HE, Kang KW, Lee DS, Chung JK, Kim SS, Suh-Kim H, Paek SH, Youn H. Dihydropyrimidine Dehydrogenase Is a Prognostic Marker for Mesenchymal Stem Cell-Mediated Cytosine Deaminase Gene and 5-Fluorocytosine Prodrug Therapy for the Treatment of Recurrent Gliomas. Theranostics 2016;6:1477-90. [PMID: 27446484 DOI: 10.7150/thno.14158] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
4 Huang B, Zhong N, Xia L, Yu G, Cao H. Sparse Representation-Based Patient-Specific Diagnosis and Treatment for Esophageal Squamous Cell Carcinoma. Bull Math Biol 2018;80:2124-36. [PMID: 29869044 DOI: 10.1007/s11538-018-0449-8] [Reference Citation Analysis]
5 Kimura M, Kuwabara Y, Mitsui A, Ishiguro H, Sugito N, Tanaka T, Shiozaki M, Naganawa Y, Takeyama H. Thymidylate synthetase and dihydropyrimidine dehydrogenase mRNA levels in esophageal cancer. Oncol Lett 2011;2:297-301. [PMID: 22866080 DOI: 10.3892/ol.2010.227] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
6 Wan X, Li Z, Ye H, Cui Z. Three-dimensional perfused tumour spheroid model for anti-cancer drug screening. Biotechnol Lett 2016;38:1389-95. [PMID: 27167883 DOI: 10.1007/s10529-016-2035-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
7 Brücher BL, Li Y, Schnabel P, Daumer M, Wallace TJ, Kube R, Zilberstein B, Steele S, Voskuil JL, Jamall IS. Genomics, microRNA, epigenetics, and proteomics for future diagnosis, treatment and monitoring response in upper GI cancers. Clin Transl Med 2016;5:13. [PMID: 27053248 DOI: 10.1186/s40169-016-0093-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
8 Fujishima H, Fumoto S, Shibata T, Nishiki K, Tsukamoto Y, Etoh T, Moriyama M, Shiraishi N, Inomata M. A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer. PLoS One 2017;12:e0188098. [PMID: 29136005 DOI: 10.1371/journal.pone.0188098] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
9 Ilem-Ozdemir D, Atlihan-Gundogdu E, Ekinci M, Halay E, Ay K, Karayildirim T, Asikoglu M. Radiolabeling and in vitro evaluation of a new 5-fluorouracil derivative with cell culture studies. J Labelled Comp Radiopharm 2019;62:874-84. [PMID: 31495966 DOI: 10.1002/jlcr.3804] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Stravopodis DJ, Karkoulis PK, Konstantakou EG, Melachroinou S, Thanasopoulou A, Aravantinos G, Margaritis LH, Anastasiadou E, Voutsinas GE. Thymidylate synthase inhibition induces p53-dependent and p53-independent apoptotic responses in human urinary bladder cancer cells. J Cancer Res Clin Oncol 2011;137:359-74. [PMID: 20425122 DOI: 10.1007/s00432-010-0891-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
11 Kachalaki S, Ebrahimi M, Mohamed Khosroshahi L, Mohammadinejad S, Baradaran B. Cancer chemoresistance; biochemical and molecular aspects: a brief overview. Eur J Pharm Sci 2016;89:20-30. [PMID: 27094906 DOI: 10.1016/j.ejps.2016.03.025] [Cited by in Crossref: 80] [Cited by in F6Publishing: 87] [Article Influence: 16.0] [Reference Citation Analysis]
12 Taddia L, D'Arca D, Ferrari S, Marraccini C, Severi L, Ponterini G, Assaraf YG, Marverti G, Costi MP. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance. Drug Resist Updat. 2015;23:20-54. [PMID: 26690339 DOI: 10.1016/j.drup.2015.10.003] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 6.2] [Reference Citation Analysis]
13 Minegaki T, Takara K, Hamaguchi R, Tsujimoto M, Nishiguchi K. Factors affecting the sensitivity of human-derived esophageal carcinoma cell lines to 5-fluorouracil and cisplatin. Oncol Lett 2013;5:427-34. [PMID: 23420099 DOI: 10.3892/ol.2012.1014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
14 Galbiatti AL, Caldas HC, Maniglia JV, Pavarino EC, Goloni-Bertollo EM. Gene expression profile of 5-fluorouracil metabolic enzymes in laryngeal cancer cell line: predictive parameters for response to 5-fluorouracil-based chemotherapy. Biomed Pharmacother 2014;68:515-9. [PMID: 24751000 DOI: 10.1016/j.biopha.2014.03.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
15 Shen Y, Tong M, Liang Q, Guo Y, Sun HQ, Zheng W, Ao L, Guo Z, She F. Epigenomics alternations and dynamic transcriptional changes in responses to 5-fluorouracil stimulation reveal mechanisms of acquired drug resistance of colorectal cancer cells. Pharmacogenomics J 2018;18:23-8. [PMID: 28045128 DOI: 10.1038/tpj.2016.91] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
16 Griffith M, Mwenifumbo JC, Cheung PY, Paul JE, Pugh TJ, Tang MJ, Chittaranjan S, Morin RD, Asano JK, Ally AA. Novel mRNA isoforms and mutations of uridine monophosphate synthetase and 5-fluorouracil resistance in colorectal cancer. Pharmacogenomics J. 2013;13:148-158. [PMID: 22249354 DOI: 10.1038/tpj.2011.65] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
17 Dzobo K, Hassen N, Senthebane DA, Thomford NE, Rowe A, Shipanga H, Wonkam A, Parker MI, Mowla S, Dandara C. Chemoresistance to Cancer Treatment: Benzo-α-Pyrene as Friend or Foe? Molecules 2018;23:E930. [PMID: 29673198 DOI: 10.3390/molecules23040930] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]